Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 2.18
SNSS's Cash to Debt is ranked higher than
61% of the 896 Companies
in the Global Biotechnology industry.

( Industry Median: 171.30 vs. SNSS: 2.18 )
SNSS' s 10-Year Cash to Debt Range
Min: 2.18   Max: No Debt
Current: 2.18

Equity to Asset -0.15
SNSS's Equity to Asset is ranked lower than
52% of the 759 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. SNSS: -0.15 )
SNSS' s 10-Year Equity to Asset Range
Min: -2.09   Max: 0.87
Current: -0.15

-2.09
0.87
F-Score: 3
Z-Score: -14.05
M-Score: -1.52
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -399.36
SNSS's Operating margin (%) is ranked higher than
59% of the 781 Companies
in the Global Biotechnology industry.

( Industry Median: -66.98 vs. SNSS: -399.36 )
SNSS' s 10-Year Operating margin (%) Range
Min: -64863.64   Max: -169.03
Current: -399.36

-64863.64
-169.03
Net-margin (%) -434.87
SNSS's Net-margin (%) is ranked higher than
58% of the 781 Companies
in the Global Biotechnology industry.

( Industry Median: -56.37 vs. SNSS: -434.87 )
SNSS' s 10-Year Net-margin (%) Range
Min: -74506.06   Max: -166.44
Current: -434.87

-74506.06
-166.44
ROA (%) -85.37
SNSS's ROA (%) is ranked higher than
53% of the 890 Companies
in the Global Biotechnology industry.

( Industry Median: -18.90 vs. SNSS: -85.37 )
SNSS' s 10-Year ROA (%) Range
Min: -778.22   Max: -24.7
Current: -85.37

-778.22
-24.7
ROC (Joel Greenblatt) (%) -138143.48
SNSS's ROC (Joel Greenblatt) (%) is ranked lower than
54% of the 868 Companies
in the Global Biotechnology industry.

( Industry Median: -189.80 vs. SNSS: -138143.48 )
SNSS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -138143.48   Max: -384.73
Current: -138143.48

-138143.48
-384.73
EBITDA Growth (%) -14.60
SNSS's EBITDA Growth (%) is ranked higher than
71% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -10.60 vs. SNSS: -14.60 )
SNSS' s 10-Year EBITDA Growth (%) Range
Min: -59.5   Max: -14.6
Current: -14.6

-59.5
-14.6
EPS Growth (%) -12.60
SNSS's EPS Growth (%) is ranked higher than
74% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: -12.60 vs. SNSS: -12.60 )
SNSS' s 10-Year EPS Growth (%) Range
Min: -60.4   Max: 20.5
Current: -12.6

-60.4
20.5
» SNSS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

SNSS Guru Trades in Q1 2013

Jim Simons 54,283 sh (New)
Louis Moore Bacon 125,000 sh (New)
Jean-Marie Eveillard Sold Out
» More
Q2 2013

SNSS Guru Trades in Q2 2013

Jim Simons Sold Out
Louis Moore Bacon Sold Out
» More
Q3 2013

SNSS Guru Trades in Q3 2013

Jean-Marie Eveillard 200,000 sh (New)
» More
Q4 2013

SNSS Guru Trades in Q4 2013

Jean-Marie Eveillard 239,956 sh (+19.98%)
» More
» Details

Insider Trades

Latest Guru Trades with SNSS

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Jean-Marie Eveillard 2013-09-30 New Buy$4.55 - $6.05 $ 5.162%200000
Jean-Marie Eveillard 2013-03-31 Sold Out 0.01%$4 - $6.49 $ 5.16-1%0
Jean-Marie Eveillard 2012-09-30 Reduce -30.24%$2.95 - $5.76 $ 5.1645%350000
Jean-Marie Eveillard 2012-06-30 New Buy0.01%$2.51 - $3.18 $ 5.1686%501727
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 32.25
SNSS's P/S is ranked lower than
72% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: 10.38 vs. SNSS: 32.25 )
SNSS' s 10-Year P/S Range
Min: 0.9   Max: 157.25
Current: 32.25

0.9
157.25

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 4.06
SNSS's Price/Median PS Value is ranked lower than
74% of the 717 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. SNSS: 4.06 )
SNSS' s 10-Year Price/Median PS Value Range
Min: 0.12   Max: 6.67
Current: 4.06

0.12
6.67
Earnings Yield (Greenblatt) 72.50
SNSS's Earnings Yield (Greenblatt) is ranked higher than
88% of the 379 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. SNSS: 72.50 )
SNSS' s 10-Year Earnings Yield (Greenblatt) Range
Min: 10.1   Max: 89.7
Current: 72.5

10.1
89.7
Forward Rate of Return (Yacktman) -68.15
SNSS's Forward Rate of Return (Yacktman) is ranked higher than
59% of the 669 Companies
in the Global Biotechnology industry.

( Industry Median: -9.87 vs. SNSS: -68.15 )
SNSS' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 7.3   Max: 8.4
Current: -68.15

7.3
8.4

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:RYIN.Germany
Sunesis Pharmaceuticals, Inc., was incorporated in the state of Delaware on February 10, 1998. It is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. It currently focuses on the development of vosaroxin for the treatment of acute myeloid leukemia, or AML. Vosaroxin is a first-in-class anti-cancer quinolone derivative, or AQD—a class of compounds that has not been used previously for the treatment of cancer. AQDs have been shown to mediate anti-tumor activity by targeting mammalian topoisomerase II, an enzyme critical for cell replication. It has built an experienced cancer drug development organization committed to advancing vosaroxin in multiple indications to improve the lives of people with cancer. In December 2010, the Company commenced enrollment of a Phase 3, multi-national, randomized, double-blind, placebo-controlled, pivotal trial of vosaroxin in combination with cytarabine in patients with relapsed or refractory AML, or the VALOR trial. The VALOR trial is designed to evaluate the effect of vosaroxin in combination with cytarabine, a widely used chemotherapy in AML, on overall survival as compared to placebo in combination with cytarabine. The Company owns development and commercialization rights to vosaroxin. It faces competition from many pharmaceutical, biopharmaceutical and biotechnology companies that are researching, developing and marketing products designed to address the treatment of cancer, including AML and ovarian cancer. In addition to regulations in the United States, the Company is subject to foreign regulations governing clinical trials and commercial sales and distribution of vosaroxin or its future drug candidates, if any.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide